网站主页 >> CAS数据库列表 >> N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
|
|
|
- CAS号:
- 861393-28-4
- 英文名:
- A-740003
- 英文别名:
- CS-451;A-740003;alpha-740003;A-740003, >=99%;A 740003; A740003;A-740003, 10 mM in DMSO;A740003 - CAS 861393-28-4 - Calbiochem;P2XRs,P2X Receptor,inhibit,A-740003,A740003,Inhibitor;(E)-N-(1-((Cyanamido(quinolin-5-ylamino)methylene)amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyp;N-(1-(3-Cyano-2-(quinolin-5-yl)guanidino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide
- 中文名:
- N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
- 中文别名:
- 化合物A 740003;化合物A 740003,10 MM DMSO 溶液;A-740003 (A 740003;A740003);N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
- CBNumber:
- CB61871931
- 分子式:
- C26H30N6O3
- 分子量:
- 474.55
- MOL File:
- 861393-28-4.mol
|
|
|
N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺化学性质
-
熔点:
-
128-129 °C
-
|
-
密度:
-
1.19±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
DMSO: soluble10mg/mL, clear (warmed)
-
|
-
形态:
-
powder
-
|
-
酸度系数(pKa):
-
14.09±0.46(Predicted)
-
|
-
颜色:
-
white to light brown
-
|
-
InChIKey:
-
PUHSRMSFDASMAE-UHFFFAOYSA-N
-
|
-
SMILES:
-
COc1ccc(CC(=O)NC(N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC
-
|
N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺性质、用途与生产工艺
A-740003 是一种有效的、选择性的 P2X7 receptor 的竞争性拮抗剂，对大鼠和人的P2X7受体的IC50值分别为18 nM和40 nM。A-740003 可在分化的人THP-1细胞中有效地阻断激动剂诱发的 IL-1β 释放和孔形成，对应的IC50值分别为156 nM和92 nM。
| Target | Value |
rat P2X7 receptor
(Cell-free assay)
|
18 nM
|
human P2X7 receptor
(Cell-free assay)
|
40 nM
|
IL-1β pore formation
(Cell-based assay)
|
92 nM
|
IL-1β release
(Cell-based assay)
|
156 nM
|
A 438079 or A 740003 (10 μM) significantly blocks the sustained phase of the BzATP-induced response. A-740003 infusion reduces SE-induced TNF-α expression in dentate granule cells. A-740003 infusions increases SE-induced neuronal death. A-740003 and A-438079 show significantly greater potency in blocking P2X7 receptor activation across all species compared with other antagonists. A-740003 and A-438079 show greater activity at rat and human, as compared with mouse P2X7 receptors. A-740003 potently blocks agonist-evoked IL-1β release with (IC
50
=156 nM) and pore formation (IC
50
=92 nM) in differentiated human THP-1 cells.
Systemic administration of A-740003 produces dose-dependent antinociception in a spinal nerve ligation model (ED
50
=19 mg/kg i.p.) in the rat. A-740003 also attenuates tactile allodynia in two other models of neuropathic pain, chronic constriction injury of the sciatic nerve and vincristine-induced neuropathy. In addition, A-740003 effectively reduces thermal hyperalgesia observed following intraplantar administration of carrageenan or complete Freund's adjuvant (ED
50
=38-54 mg/kg i.p.). A-740003 is ineffective in attenuating acute thermal nociception in normal rats and does not alter motor performance at analgesic doses.
N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2026/03/03 | S0826 | N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
A-740003 | 861393-28-4 | 5mg | 1170.34元 |
| 2026/03/03 | S0826 | N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
A-740003 | 861393-28-4 | 25mg | 3570.42元 |
N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
生产厂家
N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺 图谱信息:
861393-28-4, N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺 相关搜索:
- 抑制剂
- 天然产物
- A-740003 (A 740003;A740003)
- 化合物A 740003,10 MM DMSO 溶液
- 化合物A 740003
- N-[1-[[(氰基氨基)(5-喹啉亚氨基)甲基]氨基]-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺
- 861393-28-4
- (e)-n-(1-(2-cyano-3-(quinolin-5-yl)guanidino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide
- alpha-740003
- A-740003, 10 mM in DMSO
- P2XRs,P2X Receptor,inhibit,A-740003,A740003,Inhibitor
- N-(1-(3-Cyano-2-(quinolin-5-yl)guanidino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide
- Benzeneacetamide, N-[1-[[(cyanoamino)(5-quinolinylimino)methyl]amino]-2,2-dimethylpropyl]-3,4-dimethoxy-
- CS-451
- A 740003; A740003
- A740003 - CAS 861393-28-4 - Calbiochem
- N-[1-[(E)-[(cyanoamino)-(quinolin-5-ylamino)methylidene]amino]-2,2-dimethylpropyl]-2-(3,4-dimethoxyphenyl)acetamide
- N-[1-[[(Cyanoamino)(5-quinolinylimino)methyl]amino]-2,2-dimethylpropyl]-3,4-dimethoxybenzeneacetamide
- A-740003
- (E)-N-(1-((Cyanamido(quinolin-5-ylamino)methylene)amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyp
- A-740003, >=99%
- N-(1-{[(cyanoimino)(5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide
- N-[1-[[(Cyanoamino)(5-quinolinylimino)methyl]amino]-2,2-dimethylpropyl]-3,4-dimethoxybenzeneacetamide A-740003
- A-740003
N-[1-[[(Cyanoamino)(5-quinolinylimino)methyl]amino]-2,2-dimethylpropyl]-3,4-dimethoxybenzeneacetamide
- N-[1-[[(Cyanoamino)(5-quinolinylamino)methylene]amino]-2,2-dimethylpropyl]-3,4-dimethoxybenzeneacetamide